Literature DB >> 19907191

The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons.

Patricia A Boyle1, Aron S Buchman, Robert S Wilson, Jeremiah F Kelly, David A Bennett.   

Abstract

BACKGROUND: The apolipoprotein E (APOE) epsilon4 allele is a well-known risk factor for the development of Alzheimer's disease, but little is known about the association of the epsilon4 allele with incident mild cognitive impairment (MCI).
OBJECTIVE: Test the hypothesis that the epsilon4 allele is associated with an increased risk of developing MCI.
METHODS: More than 600 older Catholic clergy members from the Religious Orders Study without any cognitive impairment at baseline underwent APOE genotyping and detailed annual clinical evaluations for up to 16 years of follow-up (mean: 10.17 years; range: 2-16 years) to document incident MCI and rates of decline in global cognition and 5 cognitive domains (i.e. episodic memory, semantic memory, working memory, perceptual speed and visuospatial abilities).
RESULTS: During up to 16 years of annual follow-up, 339 of 607 persons (56%) developed MCI. In a proportional hazards model adjusted for age, sex and education, the presence of the APOE epsilon4 allele was associated with a 1.4-fold increased risk of incident MCI (hazard ratio: 1.36; 95% CI: 1.04, 1.78). Further, this association persisted in analyses that required MCI to persist for at least one year (hazard ratio: 1.50; 95% CI: 1.05, 2.14). Finally, the epsilon4 allele was associated with an increased rate of decline in global cognition and 4 out of 5 cognitive systems (i.e. episodic memory, semantic memory, working memory and perceptual speed).
CONCLUSION: The presence of the APOE epsilon4 allele is associated with an increased risk of MCI and a more rapid rate of cognitive decline in old age. 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19907191      PMCID: PMC2857623          DOI: 10.1159/000256662

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  37 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

3.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

4.  Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons.

Authors:  D A Evans; L A Beckett; T S Field; L Feng; M S Albert; D A Bennett; B Tycko; R Mayeux
Journal:  JAMA       Date:  1997-03-12       Impact factor: 56.272

5.  Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status.

Authors:  Denis A Evans; David A Bennett; Robert S Wilson; Julia L Bienias; Martha Clare Morris; Paul A Scherr; Liesi E Hebert; Neelum Aggarwal; Laurel A Beckett; Rajiv Joglekar; Elizabeth Berry-Kravis; Julie Schneider
Journal:  Arch Neurol       Date:  2003-02

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects.

Authors:  Susanna Tervo; Miia Kivipelto; Tuomo Hänninen; Matti Vanhanen; Merja Hallikainen; Arto Mannermaa; Hilkka Soininen
Journal:  Dement Geriatr Cogn Disord       Date:  2004-01-20       Impact factor: 2.959

8.  Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.

Authors:  D A Bennett; R S Wilson; J A Schneider; D A Evans; N T Aggarwal; S E Arnold; E J Cochran; E Berry-Kravis; J L Bienias
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

9.  Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele.

Authors:  R J Caselli; E M Reiman; D Osborne; J G Hentz; L C Baxter; J L Hernandez; G G Alexander
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

10.  Variations in case definition affect prevalence but not outcomes of mild cognitive impairment.

Authors:  John D Fisk; Heather R Merry; Kenneth Rockwood
Journal:  Neurology       Date:  2003-11-11       Impact factor: 9.910

View more
  49 in total

1.  Association of APOE with tau-tangle pathology with and without β-amyloid.

Authors:  Jose M Farfel; Lei Yu; Philip L De Jager; Julie A Schneider; David A Bennett
Journal:  Neurobiol Aging       Date:  2015-09-28       Impact factor: 4.673

2.  The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging.

Authors:  R O Roberts; Y E Geda; D S Knopman; R H Cha; V S Pankratz; B F Boeve; E G Tangalos; R J Ivnik; W A Rocca; R C Petersen
Journal:  Neurology       Date:  2012-01-25       Impact factor: 9.910

3.  Poorer Financial and Health Literacy Among Community-Dwelling Older Adults With Mild Cognitive Impairment.

Authors:  S Duke Han; Patricia A Boyle; Bryan D James; Lei Yu; David A Bennett
Journal:  J Aging Health       Date:  2015-04-22

Review 4.  Genetics and functional imaging: effects of APOE, BDNF, COMT, and KIBRA in aging.

Authors:  Goran Papenberg; Alireza Salami; Jonas Persson; Ulman Lindenberger; Lars Bäckman
Journal:  Neuropsychol Rev       Date:  2015-02-10       Impact factor: 7.444

5.  APOE ε4 genotype predicts memory for everyday activities.

Authors:  Heather R Bailey; Jesse Q Sargent; Shaney Flores; Petra Nowotny; Alison Goate; Jeffrey M Zacks
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2015-03-10

6.  A random change point model for cognitive decline in Alzheimer's disease and mild cognitive impairment.

Authors:  Lei Yu; Patricia Boyle; Robert S Wilson; Eisuke Segawa; Sue Leurgans; Philip L De Jager; David A Bennett
Journal:  Neuroepidemiology       Date:  2012-07-17       Impact factor: 3.282

7.  Principal components methods for narrow-sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes.

Authors:  Wai Lun Alan Fung; Melissa G Naylor; David A Bennett; Christoph Lange; Deborah Blacker
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2013-05-06       Impact factor: 3.568

8.  Overview and findings from the religious orders study.

Authors:  David A Bennett; Julie A Schneider; Zoe Arvanitakis; Robert S Wilson
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

9.  Mild Cognitive Impairment and Susceptibility to Scams in Old Age.

Authors:  S Duke Han; Patricia A Boyle; Bryan D James; Lei Yu; David A Bennett
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

10.  APOE and mild cognitive impairment: the Framingham Heart Study.

Authors:  Angela L Jefferson; Alexa S Beiser; Sudha Seshadri; Philip A Wolf; Rhoda Au
Journal:  Age Ageing       Date:  2014-12-11       Impact factor: 10.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.